MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution.

德国美因茨（MAINZ）和新泽西州（MAHWAH）的商业新闻（BUSINESS WIRE）--SCHOTT Pharma是制药药物控制解决方案和输送系统的先驱，KORU Medical systems（NASDAQ:KRMD）是一家领先的医疗技术公司，专注于创新和以患者为中心的大容量皮下输注溶液的开发，制造和商业化，正在联手提供大容量皮下药物输注溶液。

“We want to ensure that medications are safe and easy to use for patients and care providers around the world. By combining KORU Medical’s expertise in pump devices with our expertise in large-volume prefillable polymer syringes, we can help improve the time-to-market of infusion therapies while simplifying the subcutaneous drug infusion of large volume drugs,” says Andreas Reisse, CEO of SCHOTT Pharma.

肖特制药（SCHOTT Pharma）首席执行官安德烈亚斯·赖斯（Andreas Reisse）表示：“我们希望确保世界各地的患者和护理人员安全、易于使用药物。通过将科鲁医疗（KORU Medical）在泵设备方面的专业知识与我们在大容量可预填充聚合物注射器方面的专业知识相结合，我们可以帮助缩短输液疗法的上市时间，同时简化大容量药物的皮下药物输注。”。

The solution particularly addresses the market for treatments that are administered subcutaneously and require recurring dosing regimens, such as chronic diseases or cancer. The prefillable polymer syringes from SCHOTT Pharma that are used with KORU Medical’s Freedom System are available in large-volume formats from 5mL to 50mL to meet the need for larger infusion volumes and higher drug viscosities..

该解决方案特别针对皮下给药且需要反复给药方案的治疗市场，例如慢性病或癌症。与KORU Medical的Freedom系统一起使用的SCHOTT Pharma的可预填充聚合物注射器可提供5mL至50mL的大容量形式，以满足更大输液量和更高药物粘度的需要。。

Andreas Reisse went on to say, “As these two technologies have already demonstrated their ability to solve the subcutaneous immunoglobulin (SCIg) therapy market leader’s transition from vials to PFS, pharmaceutical companies can take comfort in a de-risked development pathway with KORU Medical’s commercialized Freedom System and SCHOTT TOPPAC® ready-to-use prefillable polymer syringes.”.

Andreas Reisse接着说，“由于这两项技术已经证明了它们能够解决皮下免疫球蛋白（SCIg）治疗市场领导者从小瓶向PFS的转变，制药公司可以通过KORU Medical的商业化Freedom系统和SCHOTT TOPPAC®即用型预充聚合物注射器在降低风险的开发途径中获得安慰。”。

Linda Tharby, President and CEO of KORU Medical Systems said, “With the shift currently happening in the SCIg market from vials to PFS, patients and health care professionals have already begun utilizing our system in conjunction with SCHOTT Pharma prefillable syringes. As the syringes come prefilled with the exact drug dosage and are capable of being delivered via the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, there are no vial preparation steps needed.

KORU Medical Systems总裁兼首席执行官琳达·塔比（Linda Tharby）表示：“随着SCIg市场目前从小瓶转向PFS，患者和医疗保健专业人员已经开始将我们的系统与肖特制药（SCHOTT Pharma）的可预充注射器结合使用。由于注射器预先填充了确切的药物剂量，并且能够通过FREEDOM60®和FreedomEdge®注射器输液驱动程序进行输送，因此不需要小瓶制备步骤。

This is both a simpler process for patients and reduces the risk of administration errors.” Linda Tharby went on to say, “KORU Medical is very excited to partner with SCHOTT Pharma to simplify drug development for our pharmaceutical partners and facilitate greater success of large volume administration for our patients.”.

这对患者来说是一个更简单的过程，并降低了管理错误的风险。”Linda Tharby接着说，“KORU Medical很高兴与SCHOTT Pharma合作，简化我们的药物合作伙伴的药物开发，并促进我们患者的大剂量给药取得更大成功。”。

About SCHOTT Pharma

关于肖特制药

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules.

人类健康很重要。这就是为什么肖特制药（SCHOTT Pharma）以科学为基础设计解决方案，以确保药物对世界各地的人们安全且易于使用。该组合包括用于注射药物的药物遏制解决方案和输送系统，从预填充玻璃和聚合物注射器到药筒，小瓶和安瓿。

Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future.

肖特制药（SCHOTT Pharma）每天都有来自60多个国家的4600多人组成的团队为全球医疗保健做出贡献。该公司在欧洲、北美、南美和亚洲的所有主要制药中心拥有16个生产基地。该公司拥有1000多项内部开发的专利和技术，并在瑞士设有最先进的研发中心，专注于为未来开发创新。

SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030.

肖特制药股份有限公司KGaA总部位于德国美因茨，作为SDAX的一部分在法兰克福证券交易所上市。它是由卡尔·蔡司基金会拥有的肖特公司的一部分。本着这种精神，肖特制药致力于社会和环境的可持续发展，并制定了到2030年实现气候中性的战略目标。

Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023..

目前，肖特制药拥有1800多家客户，其中包括前30家领先的注射剂制药制造商，2023财年的收入为8.99亿欧元。。

About KORU Medical Systems

关于KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™.

KORU Medical Systems开发、制造和商业化创新的以患者为中心的大容量皮下输液解决方案，以提高世界各地患者的生活质量。FREEDOM注射器输液系统（“FREEDOM系统”）目前包括FREEDOM60®和FreedomEdge®注射器输液驱动器、Precision Flow Rate Tubbing™和HIgH-Flo皮下安全针头套件™。

The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its novel therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories.

Freedom系统于1994年首次获得FDA批准，用于患者在家中自我管理和/或由医疗保健专业人员在门诊输液中心分娩。通过其新型疗法业务，KORU Medical在药物开发过程中为生物制药公司提供用于可行性/临床试验的产品，并根据需要定制Freedom系统，用于多种药物类别的临床和商业用途。